A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02

Choi, Yoon Hee; Oh, Sang Cheul; Kim, Jun Suk; Nam, Seung Hyun; Kim, Bong Seog; Cho, Sang‐Hee; Chung, Ik Joo; Song, Eun Kee; Yim, Chang Yeol; Baek, Jin Ho; Jeung, Hei Cheul; Hong, Young Seon; Yang, Sung Hyun; Kang, Hye Jin

doi:10.1007/s00280-012-1956-1

Cited by 5 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some phase II trials [14,15,16], a 3-week cycle SOX-based regimen for advanced patients, produced an ORR of over 45%, and a median time to progression and OS of 4.6-6.6 months and 7.8-16.5 months, respectively. The efficacy outcome of the SOX regiment in our study was comparable to that reported previously; however, the commonly observed adverse event rates were lower in our study compared to those in the trials conducted in Japan and Korea [17]. …”

Section: Discussionsupporting

confidence: 66%

Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

Wang

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

Background: Both docetexal plus S-1 (DS) and oxaliplatin plus S-1 (SOX) are active regimens currently used in patients with advanced gastric cancer. In this retrospective study, efficacy and safety of these 2 combination regimens were evaluated. Patients and Methods: Patients received docetaxel infusion 75 mg/m² in the DS group or oxaliplatin infusion 130 mg/m² in the SOX group at day 1 of each 3-week cycle. S-1 40 mg/m² was administered orally twice daily on days 1-14 in the 3-week cycle in both groups. Progression-free survival (PFS), overall survival (OS) and safety perimeters were evaluated. Results: 84 patients were retrospectively evaluated in the study: 36 patients in the DS group and 48 patients in the SOX group. The median PFS was 6.55 months in the DS group and 5.73months in the SOX group. The median OS was 13.97 in the DS group and 13.13 months in the SOX group. The overall response rates were 41.7% and 43.8% and the disease control rates were 77.8% and 87.5% for DS and SOX, respectively. The most frequent grade 3 and 4 toxicities were thrombocytopenia for DS (19.4%) and anemia for SOX (12.5%). Conclusion: Both regimens were active and well tolerated in advanced gastric cancer patients.

show abstract

Section: Discussionsupporting

confidence: 66%

Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

Wang

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Therefore, the role of palliative chemotherapy in the treatment of gastric cancer is especially important. The commonly used first‐line combination chemotherapy regimens consist of a fluoropyrimidine plus a platinum agent with or without docetaxel [Van Cutsem et al, ; Kim et al, ; Choi et al, ; Jiang et al, ]. However, the response to chemotherapy differs widely among GC patients, and patients who show a poor response to first‐line chemotherapy always have a poor prognosis.…”

mentioning

confidence: 99%

miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer

Huang

Wang

et al. 2014

J of Cellular Biochemistry

View full text Add to dashboard Cite

We previously identified five miRNAs (miR-1, miR-20a, miR-27a, miR-34a, and miR-423-5p) that are up-regulated in gastric cancer. The goal of this study was to investigate the value of these miRNAs as potential biomarkers for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer patients who received first-line chemotherapy. A total of 82 patients with metastatic or recurrent GC receiving first-line chemotherapy were included in our study. The expression levels of the five miRNAs were evaluated using hydrolysis probe-based stem-loop quantitative reverse transcription polymerase chain reaction (qRT-PCR) in individual samples before first-line chemotherapy. Patients receiving first-line chemotherapy with fluoropyrimidine combined with oxaliplatin or paclitaxel were chosen for the chemosensitivity analysis. The relationships between expression of the five-miRNAs and clinicopathological parameters, response to chemotherapy and prognosis were analyzed statistically. Patients with higher miRNA1 expression levels tended to have a higher rate of liver metastasis, and higher miRNA34a expression levels occurred more frequently in males (P = 0.022). The expression of the remaining three miRNAs showed no obvious relationship to any of the clinicopathological features. The partial response rates of the patients with high miRNA1 expression and low miRNA1 expression were 11.1% and 23.1%, respectively (P = 0.048). Similar results were observed for miRNA27a (the partial response rate was 7.7% vs. 25.9%, P = 0.018). Patients with up-regulated miRNA27a expression had a significantly worse overall survival (OS) than patients with lower miRNA27a expression (P = 0.024). In patients with MRGC, miRNA27a is a potential biomarker for predicting resistance to fluoropyrimidine-based chemotherapy and a novel prognostic marker for gastric cancer.

show abstract

“…However, the overall survival of salvage RT group was comparable to other studies implementing systemic chemotherapy alone, implying that each of RT or chemotherapy may have effect on LN recurrences of gastric cancer. Median OS of the current study was 29 months which is better than those of historical controls better than those of historical controls [10-14]. Although many clinical or pathologic factors can contribute to the outcomes, aggressive treatment strategies including local and systemic modalities may be attributed to the outstanding outcomes.…”

Section: Discussionmentioning

confidence: 85%

“…Koizumi et al [13] demonstrated that combination chemotherapy with docetaxel, cisplatin, and S-1 is a well-tolerated and highly active regimen for advanced or recurrent gastric cancer, in which the median OS and PFS were 18.5 and 8.7 months, respectively. Choi et al [14] performed a phase II study of docetaxel combined with oxaliplatin for recurrent gastric cancer. With the effectiveness of combination chemotherapy, the median OS and PFS were 13.8 and 5.3 months, respectively.…”

Section: Discussionmentioning

confidence: 99%

Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer

et al. 2013

View full text Add to dashboard Cite

PurposeTo evaluate the role of salvage radiotherapy (RT) for the treatment of regional lymph node recurrence (RLNR) after radical surgery in advanced gastric cancer.Materials and MethodsWe retrospectively analyzed medical records of 26 patients who underwent salvage treatment after diagnosis of RLNR between 2006 and 2011. Patients with peritoneal seeding or distant metastasis were excluded. Eighteen patients received RT with or without chemotherapy and the other 8 did chemotherapy only without RT. A three-dimensional conformal RT was performed with median dose of 56 Gy (range, 44 to 60 Gy). Sixteen patients had fluoropyrimidine-based chemotherapy, 5 did taxane-based chemotherapy, and irinotecan was applied in 4.ResultsWith a median follow-up of 20 months (range, 5 to 57 months), median overall survival (OS) and progression-free survival (PFS) after diagnosis of RLNR were 29 months and 12 months in the entire patients, respectively. Radiotherapy (p = 0.007) and disease-free interval (p = 0.033) were statistically significant factors for OS in multivariate analysis. Median OS was 36 months in patients who received RT and 16 months in those who did not. Furthermore, delivery of RT (p < 0.001), complete remission after salvage treatment (p = 0.040) and performance status (p = 0.023) were associated with a significantly better PFS. Gastrointestinal toxicities from RT were mild in most patients.ConclusionSalvage RT combined with systemic chemotherapy may be an effective treatment managing RLNR from advanced gastric cancer.

show abstract

A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02

Abstract: Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy.

Cited by 5 publications

References 35 publications

Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer

Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer

Contact Info

Product

Resources

About